-
-
-
-
-
-
-
Cosmos Health posts 29% revenue rise but widens net loss in Q2 2026
-
-
-
-
-
-
-
Cosmos Health issues 2026-2029 guidance targeting $200m revenue by 2029
-
-
-
-
-
-
-
Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway,
-
-
-
-
-
-
-
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
-
-
-
-
-
-
-
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
-
-
-
-
-
-
-
Cosmos Health (COSM) Issues Guidance
-
-
-
-
-
-
-
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)
-
1,237,817 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


